Loading…
Loading…
AARD DEADLINE NOTICE: Faruqi and Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026PR NewswireNEW YORK,
Palatin Reports Fiscal Year 2026 Financial Results and Provides Business UpdatePR NewswirePRINCETON, N.J., Sept. 28, 2026Programs are focused on rare obesity di
AARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (NASDAQ: AARD) to Filing of Securities Fraud Class ActionPR NewswireSAN FRANCISCO,
Aardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadli
Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 De
Aardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadli
[url="]Faruqi and Faruqi, LLP[/url], a leading national securities law firm, is investigating potential claims against Aardvark Therapeutics, Inc. (âAardvarkâ
RENSSELAER, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- ConSynance Therapeutics, Inc. (“ConSynance”), a clinical-stage biotechnology company developing first-in-class therapies for neurobehavioral symptoms in rare neurodevelopmental disorders, today announced that the first participant has been dosed in its Phase 2a clinical trial of CSTI-500 for Prader-Willi syndrome (PWS), marking a significant clinical development milestone for the program.
SEC filings for PWS aren't indexed yet (common for recently launched funds). Browse the issuer's filings on SEC EDGAR directly.